Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

C OPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company valued at $7.15 billion, has initiated a share repurchase program, with plans to buy back up to $18.25 million of its ...

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

Ascendis Pharma ended 2024 with strong momentum, driven by SKYTROFA’s revenue growth and YORVIPATH’s U.S. launch. With €665 million in cash and multiple product expansions planned for 2025 ...

Ascendis Pharma A/S (NASDAQ:ASND) defied analyst predictions to release its annual results, which were ahead of market expectations. The overall earnings picture was okay, with revenues of €364m ...

Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.